AKNA HEALTH LLC

Medtech · Private

CerviGuard, a diagnostic platform using trophoblast-specific biomarkers in cervical fluid samples for first-trimester pregnancy risk stratification

Grants
$2.7M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Assay development for the assessment of pregnancy risks in early pregnancy$368,190
Federal grantDepartment of Health and Human Services · Phase I · Point-of-care testing for perinatal risks in early pregnancy$351,600
Federal grantDepartment of Health and Human Services · Phase II · Assay development for the assessment of pregnancy risks in early pregnancy$1,949,879
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1060STREAM DX, INC.——
1061Serimmune—$20M
106234 Lives, PBC——
1063AKNA HEALTH LLC——
1064Neuraptive Therapeutics, Inc.—$30M
1065Vivamed, Inc.—$3.1M
1066Intelligent Fingerprinting Ltd—$23M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.